These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 23636665)
1. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients. Giacomini E; Severa M; Rizzo F; Mechelli R; Annibali V; Ristori G; Riccieri V; Salvetti M; Coccia EM Eur J Immunol; 2013 Jul; 43(7):1963-72. PubMed ID: 23636665 [TBL] [Abstract][Full Text] [Related]
2. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis. Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488 [TBL] [Abstract][Full Text] [Related]
3. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415 [TBL] [Abstract][Full Text] [Related]
4. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480 [TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). Tao Y; Zhang X; Markovic-Plese S J Neuroimmunol; 2016 Sep; 298():181-8. PubMed ID: 27609294 [TBL] [Abstract][Full Text] [Related]
6. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519 [TBL] [Abstract][Full Text] [Related]
7. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524 [TBL] [Abstract][Full Text] [Related]
8. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. Zhang X; Jin J; Tang Y; Speer D; Sujkowska D; Markovic-Plese S J Immunol; 2009 Mar; 182(6):3928-36. PubMed ID: 19265172 [TBL] [Abstract][Full Text] [Related]
9. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Hamamcioglu K; Reder AT Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069 [TBL] [Abstract][Full Text] [Related]
10. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513 [TBL] [Abstract][Full Text] [Related]
11. IFN-β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. Severa M; Rizzo F; Giacomini E; Annibali V; Gafa V; Romano S; Buscarinu MC; Fornasiero A; Salvetti M; Coccia EM J Interferon Cytokine Res; 2015 Sep; 35(9):668-81. PubMed ID: 25923141 [TBL] [Abstract][Full Text] [Related]
12. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209 [TBL] [Abstract][Full Text] [Related]
13. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756 [TBL] [Abstract][Full Text] [Related]
14. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. Chiarini M; Serana F; Zanotti C; Capra R; Rasia S; Rottoli M; Rovaris M; Caputo D; Cavaletti G; Frigo M; Frigeni B; Clerici R; Rezzonico M; Caimi L; Imberti L Mult Scler; 2012 Jun; 18(6):788-98. PubMed ID: 22086901 [TBL] [Abstract][Full Text] [Related]
15. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161 [TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427 [TBL] [Abstract][Full Text] [Related]
17. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198 [TBL] [Abstract][Full Text] [Related]
18. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628 [TBL] [Abstract][Full Text] [Related]
19. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Zhang X; Markovic-Plese S Clin Neurol Neurosurg; 2010 Sep; 112(7):641-5. PubMed ID: 20570038 [TBL] [Abstract][Full Text] [Related]
20. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis. Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]